Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bepotastine besilate - Mitsubishi Tanabe Pharma Corporation

Next Previous
Drug Profile

Bepotastine besilate - Mitsubishi Tanabe Pharma Corporation

Alternative Names: Bepotastine; Bepreve; Betotastine; Betotastine besilate; Talion; TAU-284

Latest Information Update: 25 Jan 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ube Industries
  • Developer ISTA Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Ube Industries
  • Class Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Butyric acids; Chlorobenzenes; Eye disorder therapies; Piperidines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Pruritus; Urticaria
  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 10 Feb 2020 Dong-A ST completes a phase I trial in Healthy volunteers in South Korea (NCT03932435)
  • 30 Dec 2019 Registered for Allergic rhinitis (In children, In adolescents, In adults) in Thailand (PO)
  • 30 Dec 2019 Registered for Pruritus (In children, In adolescents, In adults) in Thailand (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top